NF-kB p65 antibody (pSer536)
-
- Target See all NF-kB p65 (NFkBP65) Antibodies
- NF-kB p65 (NFkBP65) (Nuclear Factor-kB p65 (NFkBP65))
-
Binding Specificity
- pSer536
-
Reactivity
- Human
-
Host
- Rabbit
-
Clonality
- Polyclonal
-
Conjugate
- This NF-kB p65 antibody is un-conjugated
-
Application
- Western Blotting (WB), Immunohistochemistry (IHC), ELISA
- Supplier Product No.
- 600-401-265
- Supplier
- Rockland
- Purpose
- NFkB p65 phospho S536 Antibody
- Cross-Reactivity (Details)
- This antibody is specific for human p65 (RelA) protein phosphorylated at S536.
- Characteristics
- Synonyms: rabbit anti-NFKB p65 pS536 antibody, rabbit anti-p65 antibody, rabbit anti-RelA antibody, NFKB, NFkß, NF-kB, NF-kappaB, NFkappaB, Transcription factor p65, Nuclear factor NF-kappa-B p65 subunit, Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3, RELA, NFKB3
- Purification
- This product was affinity purified from monospecific antiserum by immunoaffinity chromatography using phospho-peptide coupled to agarose beads followed by solid phase adsorption against nonphospho-peptide.
- Sterility
- Sterile filtered
- Immunogen
-
Immunogen: This affinity purified antibody was prepared from whole rabbit serum produced by repeated immunizations with a synthetic peptide corresponding to a c-terminal region near phospho Serine S536 of human p65 (RelA) protein.
Immunogen Type: Conjugated Peptide
- Isotype
- IgG
- Top Product
- Discover our top product NFkBP65 Primary Antibody
-
-
- Application Notes
-
Immunohistochemistry Dilution: 5 μg/mL
Application Note: This affinity purified antibody has been tested for use in ELISA, immunohistochemistry and western blotting. Specific conditions for reactivity should be optimized by the end user. By western blot, a band approximately 65 kDa in size corresponding to phosphorylated p65 (RelA) protein is expected in the appropriate cell lysate or extract. This phospho-specific polyclonal antibody reacts with human p65 (RelA) pS536 and shows minimal reactivity by western blot with non-phosphorylated p65 (RelA) and minimal reactivity by ELISA against the non-phosphorylated form of the immunizing peptide.
Western Blot Dilution: 1:200 - 1:2,000
ELISA Dilution: 1:1,000 - 1:6,000
Other: User Optimized
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- 1.0 mg/mL
- Buffer
-
Buffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
Stabilizer: None
Preservative: 0.01 % (w/v) Sodium Azide - Preservative
- Sodium azide
- Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Storage
- 4 °C,-20 °C
- Storage Comment
- Store vial at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
- Expiry Date
- 12 months
-
-
Linear ubiquitination is involved in the pathogenesis of optineurin-associated amyotrophic lateral sclerosis." in: Nature communications, Vol. 7, pp. 12547, (2016) (PubMed).
: "Morin (3,5,7,2',4'-Pentahydroxyflavone) abolishes nuclear factor-kappaB activation induced by various carcinogens and inflammatory stimuli, leading to suppression of nuclear factor-kappaB-regulated ..." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 13, Issue 7, pp. 2290-7, (2007) (PubMed).
: "
-
Linear ubiquitination is involved in the pathogenesis of optineurin-associated amyotrophic lateral sclerosis." in: Nature communications, Vol. 7, pp. 12547, (2016) (PubMed).
-
- Target
- NF-kB p65 (NFkBP65) (Nuclear Factor-kB p65 (NFkBP65))
- Alternative Name
- RELA (NFkBP65 Products)
- Background
- Background: This antibody is designed, produced, and validated as part of a collaboration with the National Cancer Institute (NCI) and is suitable for Cancer, Immunology and Nuclear Signaling research. NFkB was originally identified as a factor that binds to the immunoglobulin kappa light chain enhancer in B cells. It was subsequently found in non-B cells in an inactive cytoplasmic form consisting of NFkB bound to IkB. NFkB was originally identified as a heterodimeric DNA binding protein complex consisting of p65 (RelA) and p50 (NFKB1) subunits. Other identified subunits include p52 (NFKB2), cRel, and RelB. The p65, cRel, and RelB subunits are responsible for transactivation. The p50 and p52 subunits possess DNA binding activity but limited ability to transactivate. p52 has been reported to form transcriptionally active heterodimers with the NFkB subunit p65, similar to p50/p65 heterodimers. Lowlevels of p52 and p50 homodimers can also exist in cells. The heterodimers of p52/p65 and p50/p65 are regulated by physical inactivation in the cytoplasm by IkB-alpha. IkB-alpha binds to the p65 subunit, preventing nuclear localization, and DNA binding. Activators mediate a rapid phosphorylation of IkB by IkB kinase (IKK), which results in subsequent ubiquitination and proteolytic degradation. NFkB is then transported to the nucleus, where it activates transcription of target genes through binding to NFkB target sequences within the promoter. The HTLV-I protein Tax can induce constitutive NFkB activation through phosphorylation of both IkB-alpha and IkB-beta. The transforming protein Tax inhibits p53 transcriptional activity through the NFkB signaling pathway, specifically via the p65 (RelA) subunit. The inhibition of p53 activity is dependent upon phosphorylation of p65 (RelA) at S536 by the upstream kinase IKKβ.
- Gene ID
- 5970, 223468676
- UniProt
- Q04206
- Pathways
- NF-kappaB Signaling, RTK Signaling, TCR Signaling, TLR Signaling, Fc-epsilon Receptor Signaling Pathway, Neurotrophin Signaling Pathway, Activation of Innate immune Response, Cellular Response to Molecule of Bacterial Origin, Hepatitis C, Toll-Like Receptors Cascades, S100 Proteins
-